Recurrent glomerulonephritis after renal transplantation is the third most common cause of allograft loss, the most frequent of which is associated with IgA nephropathy (IgAN). This study aims to provide a systematic review of the risk factors associated with recurrent IgAN after renal transplantation. We searched English and Chinese databases, including PubMed, Embase, Web of Science, CNKI, and others, and included all case-control studies involving risk factors for recurrent IgAN after renal transplantation from the databases’ establishment to March 2022. Data were analyzed using the Stata 12.0. A total of 20 case-control studies were included in the meta-analysis, with 542 patients with recurrent IgAN and 1385 patients without recurrent IgAN. The results showed that donor age (standardized mean difference [SMD] −0.13 [95% confidence interval (CI) −0.26, −0.001];P═ 0.048), patient age at transplantation (SMD −0.41 [95% CI −0.53, −0.29];P< 0.001), time from diagnosis to end-stage renal disease (SMD −0.42 [95% CI −0.74, −0.10];P═ 0.010), previous transplantation (odds ratio [OR] 1.73 [95% CI 1.06, 2.81];P═ 0.027), living donor (OR 1.86 [95% CI 1.34, 2.58];P< 0.001), related donor (OR 2.64, [95% CI 1.84, 3.79];P< 0.001), tacrolimus use (OR 0.71 [95% CI 0.52, 0.98];P═ 0.035), basiliximab use (OR 0.39 [95% CI 0.27, 0.55];P< 0.001), proteinuria (SMD 0.42 [95% CI 0.13, 0.71];P═ 0.005), and serum IgA level (SMD 0.48 [95% CI 0.27, 0.69];P< 0.001) were associated with recurrent IgAN after renal transplantation. In general, tacrolimus and basiliximab use were the protective factors against recurrent IgAN after renal transplantation, whereas donor age, patient age at transplantation, time from diagnosis to end-stage renal disease, previous transplantation, living donor, related donor, proteinuria, and serum IgA level were the risk factors for recurrent IgAN after renal transplantation. Clinical decision making should warrant further consideration of these risk factors.